Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT07331402

A Clinical Study Evaluating the Pharmacokinetics and Pharmacodynamics of HSK39004 Inhalation Suspension in COPD Patients

A Random, Single Blind, Positive Control, Crossover Design Clinical Study to Evaluate the Pharmacokinetics and Pharmacodynamics of HSK39004 Inhalation Suspension in COPD Patients

Status
Active Not Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
12 (estimated)
Sponsor
Haisco Pharmaceutical Group Co., Ltd. · Industry
Sex
All
Age
40 Years – 80 Years
Healthy volunteers
Not accepted

Summary

This is a random, single blind, positive control, crossover design clinical study to evaluate the pharmacokinetics and pharmacodynamics of HSK39004 inhalation suspension in COPD patients

Conditions

Interventions

TypeNameDescription
DRUGHSK39004 inhalation suspensionHSK39004 inhalation suspension , Inhale through the mouth, 3mg each time, twice a day; Ohtuvayre inhalation suspension, Inhale through the mouth, 3mg each time, twice a day

Timeline

Start date
2025-07-28
Primary completion
2025-12-30
Completion
2026-08-30
First posted
2026-01-09
Last updated
2026-01-09

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT07331402. Inclusion in this directory is not an endorsement.